Lumida
/VEEV
⌘K
Veeva Systems Inc

Veeva Systems Inc

VEEV
$262.40USD+0.54%+1.42 today

MARKET CAP

42.1B

P/E (TTM)

48.2x

FWD P/E

DAY RANGE

$260 – $264

52W RANGE

$148
$311

AI Summary

Stalk
StalkMedium

In a Stage 2 uptrend with bullish medium- and long-term structure, VEEV is digesting a pullback into the $258–$262 support zone around the rising EMAs amid overbought conditions—new entries are deferred until a confirmed bounce off these levels to optimize risk.

  • Q4 2026 revenue $836M (+16% YoY) and $366M op income beat guidance
  • FY27 revenue guidance raised to $3.5B after Q1 rev of $883M
  • Top 20 CRM clients exploring alternatives, risking ~20% revenue loss
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Viva Systems, Inc. (NYSE: VEEV) operates primarily in the life sciences software sector, specializing in cloud-based solutions for clinical trials, data management, and regulatory compliance. Viva is making significant strides in developing AI-driven products and services, particularly through its Vault platform, which enhances operational efficiency for pharmaceutical and biotechnology companies. The company is positioned as a leader in a growing and evolving industry, with a strong emphasis on integrated and innovative solutions tailored for its strategic customers.

Bull says

  • Q4 2026 revenue $836M (+16% YoY) and $366M op income beat guidance
  • FY27 revenue guidance raised to $3.5B after Q1 rev of $883M
  • Vault AI products forecast to improve client efficiency ~15%
  • DCF implies $303 intrinsic vs $218 market price (~20% upside)
  • High profitability and growth factors, plus strong earnings yield
  • Customer base up 5% YoY, driven by small/mid-sized biotechs

Bear says

  • Top 20 CRM clients exploring alternatives, risking ~20% revenue loss
  • P/E ~40.5x exceeds sector average, suggesting valuation risk
  • AI rollout execution may disrupt client workflows if adoption lags
  • Macro uncertainty could constrain biotech funding, impacting project cycles
  • Negative liquidity and elevated leverage risk pressuring cash flow
  • Weak price momentum and negative investor sentiment dampen outlook

Investment themes with VEEV

Quality -0.56%

Companies with strong fundamentals and stability

NVDA · AAPL · MSFT
Health Care Providers -0.37%

UNH · CVS · HCA

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-27-2026neutral

Transcript signals

Bull points

  • we're pleased with the $35 million raise there to full-year guidance, which is roughly in line with the revenue increase.
  • We expect that to continue to be a meaningful driver of growth in commercial going forward and in the balance of the year.
  • We continue to see good growth in both areas of Cross-X, the measurement business, which is a little more consistent subscription-like business, as well as the audiences business, which is usage-based.

Bear points

  • On the macro environment, I think what we're seeing overall is while there's still elevated uncertainty, there's really no change. It's fairly stable in that level of uncertainty.
  • On the macro environment, I think what we're seeing overall is while there's still elevated uncertainty, there's really no change. It's fairly stable in that level of uncertainty.
  • In 2025, I expect that to be some of the lower years.
Read full transcript analysis ›